InvaGen Pharmaceuticals, Inc.: Drug Recall

Recall #D-0220-2024 · 11/17/2023

Class I: Dangerous

Recall Details

Recall Number
D-0220-2024
Classification
Class I
Product Type
Drug
Recalling Firm
InvaGen Pharmaceuticals, Inc.
Status
Completed
Date Initiated
11/17/2023
Location
Central Islip, NY, United States
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1240 boxes

Reason for Recall

Defective Container: powder may leak out of the pouch

Product Description

Vigabatrin for Oral Solution, USP 500 mg per packet, 50 packets per box, Rx Only, Manufactured by: InvaGen Pharmaceuticals, Inc., (a subsidiary of Cipla Ltd.), Hauppauge, NY, 11788, Manufactured for: Cipla USA, Inc., Warren, NJ 07059, NDC 69097-964-53

Distribution Pattern

Nationwide within the United States

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.